...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Top-Line Data Expected September 2019 for BETonMACE Phase 3 Cardiovascular Outcomes Trial for Apabetalone

Message: "57% relative risk reduction of MACE in patients with diabetes mellitus (DM) and CVD..."

Has this been shared here before?  From the American Diabetics Association:


Dated July 2018....if it was posted while I was down east I might have missed it.  57% seems a little to precise to be a guesstimate....55%, 60%....those are round figures, 57% seems odd with the trial still on going.

New Message
Please login to post a reply